Loading...

Psyence Biomedical Ltd. Warrant

PBMWW•NASDAQ
Healthcare
Biotechnology
$0.02
$0.001(3.98%)

Psyence Biomedical Ltd. Warrant (PBMWW) Stock Overview

Explore Psyence Biomedical Ltd. Warrant’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 65.1/100

Key Financials

Market Cap1.3K
P/E Ratio0.00
EPS (TTM)N/A
ROE9.16%
Fundamental Analysis

AI Price Forecasts

1 Week$0.02
1 Month$0.01
3 Months$0.00
1 Year Target$0.01

PBMWW Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Psyence Biomedical Ltd. Warrant (PBMWW) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 48.23, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.01.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 0.00 and a market capitalization of 1.3K. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

48.23RSI (14)
0.00MACD
69.56ADX
Stats data is not available for PBMWWStats details for PBMWW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for PBMWWAnalyst Recommendations details for PBMWW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.

CEO

Neil Maresky

Headquarters

121 Richmond Street West, Toronto, ON

Founded

1970

Frequently Asked Questions

;